The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

被引：17
|
作者：
Lonardi, S. [1 ]
Pietrantonio, F. [2 ]
Llavero, N. Tarazona [3 ]
Viladot, C. Montagut [4 ]
Bianchi, A. Sartore [5 ]
Zampino, M. G. [6 ]
Fernandez, M. E. Elez [7 ]
Vivas, C. Santos [8 ]
Mandala, M. [9 ]
Tamberi, S. [10 ]
Sciallero, M. S. [11 ]
Munoz, S. [12 ]
Lazzari, L. [13 ]
Luraghi, P. [13 ]
Torri, V. [14 ]
Cervantes, A.
Bardelli, A. [15 ]
Tabernero, J.
Siena, S.
Marsoni, S. [13 ]
机构：
[1] IOV Ist Oncol Veneto IRCCS, Oncol, Padua, Italy
[2] Fdn IRCCS, Dept Med Oncol, Ist Nazl Tumori, Milan, Italy
[3] Univ Valencia, INCLIVA Biomed Res Inst, Dept Med Oncol, Valencia, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Univ Milano La Statale, Dipartimento Oncol Emato Oncol, ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[6] IEO Ist Europeo Oncol, Dept Med Oncol, Milan, Italy
[7] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[8] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Med Oncol Dept, Lhospitalet De Llobregat, Spain
[9] Univ Perugia, Santa Maria Misericordia, Univ Hosp Perugia, Oncol, Perugia, Italy
[10] AUSL Romagna, Osped Infermi, Oncol Unit, Faenza, Ravenna, Italy
[11] IRCCS Osped Policlin San Martino, Med Oncol 1 Dept, Genoa, Italy
[12] Vall Hebron Inst Oncol VHIO, Cellex Ctr, Acad CRO, Barcelona, Spain
[13] IFOM AIRC Inst Mol Oncol, Precis Oncol Unit, Milan, Italy
[14] Ist Ric Farmacol Mario Negri IRCCS, Oncol, Milan, Italy
[15] IFOM AIRC Inst Mol Oncol, Gen Canc & Targeted Therapies, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA28
引用
收藏
页码：S1268 / S1269
页数：2
相关论文
共 50 条
  • [31] High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer
    Ji Soo Park
    Hong Jae Chon
    Hei-Cheul Jeung
    Sang Joon Shin
    Sun Young Rha
    Joong Bae Ahn
    Kang Young Lee
    Nam Kyu Kim
    Hyun Cheol Chung
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 2051 - 2059
  • [32] High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal
    Babcock, Blake D.
    Aljehani, Mayada A.
    Jabo, Brice
    Choi, Audrey H.
    Morgan, John W.
    Selleck, Matthew J.
    Luca, Fabrizio
    Raskin, Elizabeth
    Reeves, Mark E.
    Garberoglio, Carlos A.
    Lum, Sharon S.
    Senthil, Maheswari
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (07) : 1980 - 1985
  • [33] High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal
    Blake D. Babcock
    Mayada A. Aljehani
    Brice Jabo
    Audrey H. Choi
    John W. Morgan
    Matthew J. Selleck
    Fabrizio Luca
    Elizabeth Raskin
    Mark E. Reeves
    Carlos A. Garberoglio
    Sharon S. Lum
    Maheswari Senthil
    Annals of Surgical Oncology, 2018, 25 : 1980 - 1985
  • [34] Recent approaches to identifying biomarkers for high-risk stage II colon cancer
    Akiyoshi, Takashi
    Kobunai, Takashi
    Watanabe, Toshiaki
    SURGERY TODAY, 2012, 42 (11) : 1037 - 1045
  • [35] Recent approaches to identifying biomarkers for high-risk stage II colon cancer
    Takashi Akiyoshi
    Takashi Kobunai
    Toshiaki Watanabe
    Surgery Today, 2012, 42 : 1037 - 1045
  • [36] Duration of FOLFOX adjuvant chemotherapy in high-risk stage II and stage III colon cancer with deficient DNA mismatch repair.
    Wu, Zehua
    Hu, Huabin
    Wang, Chao
    Huang, Yan
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] High-risk Stage II Colon Cancer: Not All Risks Are Created Equal
    Babcock, B. D.
    Aljehani, M.
    Jabo, B.
    Choi, A.
    Morgan, J. W.
    Selleck, M. J.
    Luca, F.
    Raskin, E.
    Reeves, E.
    Garberoglio, C. A.
    Lum, S. S.
    Senthil, M.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S34 - S34
  • [38] Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial
    Ruzzo, A.
    Galli, F.
    Galli, F.
    Rulli, E.
    Lonardi, S.
    Zagonel, V.
    Ronzoni, M.
    Ionta, M. T.
    Pella, N.
    Mucciarini, C.
    Labianca, R.
    Veltri, E.
    Sozzi, P.
    Barni, S.
    Nicolini, M.
    Biondi, E.
    Bramati, A.
    Turci, D.
    Buscaglia, M.
    Magnani, M.
    Graziano, F.
    ANNALS OF ONCOLOGY, 2017, 28 : 4 - 5
  • [39] High postoperative carcinoembryonic antigen as an indicator of high-risk stage II colon cancer
    Morimoto, Yoshihiro
    Takahashi, Hidekazu
    Arita, Asami
    Itakura, Hiroaki
    Fujii, Makoto
    Sekido, Yuki
    Hata, Tsuyoshi
    Fujino, Shiki
    Ogino, Takayuki
    Miyoshi, Norikatsu
    Uemura, Mamoru
    Matsuda, Chu
    Yamamoto, Hirofumi
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Eguchi, Hidetoshi
    ONCOLOGY LETTERS, 2022, 23 (05)
  • [40] Comparison between oxaliplatin therapy and capecitabine monotherapy for high-risk stage II-III elderly patients with colon cancer
    Park, Jueun
    Baik, HyungJoo
    Kang, Sang Hyun
    Seo, Sang Hyuk
    Kim, Kwang Hee
    Oh, Min Kyung
    Lee, Hong Sub
    Lee, Sang Heon
    Kim, Ki Hyang
    An, Min Sung
    ASIAN JOURNAL OF SURGERY, 2022, 45 (01) : 448 - 455
12345